$SGTX News
Last published 3y ago
- 3y agoLLYSGTXLilly Completes Acquisition of Sigilon TherapeuticsPR NewswireINDIANAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ:SGTX). The acquisition allows Lilly to
- 3y agoCCFCIRHCCISGTXMoore Kuehn Encourages SGTX, CIR, HCCI, and CCF Investors to Contact Law FirmGlobeNewswireNEW YORK, July 24, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoFREYWFCJPMBAC+7Stocks making the biggest moves midday: Occidental Petroleum, Wells Fargo, Micron, Joby and moreCNBCThese are the stocks posting the largest moves in midday trading.
- 3y agoLLYSGTXLilly to Acquire Sigilon TherapeuticsPR NewswireINDIANAPOLIS and CAMBRIDGE, Mass., June 29, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Sigilon Therapeutics, Inc. (NASDAQ:SGTX) today announced a definitive agreement for Lilly to acquire Sigilon, a
- 3y agoSGTXSigilon Announces Reverse Stock Split of Common StockGlobeNewswireCAMBRIDGE, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX) today announced it will effect a one-for-13 reverse stock split of its issued and outstanding common stock. Sigilon
- 3y agoSGTXSigilon Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsGlobeNewswireSIG-002, Sigilon's lead program for the treatment of diabetes, transitioning to IND-enabling and NHP studies in the second half of 2023 Pipeline prioritization extends anticipated cash runway into 2025 CAMBRIDGE,
- 3y agoSGTXVCELOCATATRSDimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior AdvisorPR NewswireCHICAGO, May 2, 2023 /PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments of Paul K. Wotton, Ph.D., to the board
- 3y agoSGTXSigilon Therapeutics to Present at the Needham Virtual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for acute and chronic diseases through its Shielded Living
- 3y agoSGTXSigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsGlobeNewswireAdvancing IND-enabling activities for lead program in diabetes, SIG-002, with plans to conduct non-human primate studies in second half of 2023 SIG-002 demonstrated efficacy and durability in in vivo mouse models for up
- 3y agoSGTXKytopen Announces Foundation of New Scientific Advisory Board Joined by Cullen Buie, Ph.D., Omid Veiseh, Ph.D., Stanley Qi, Ph.D., Katie Galloway, Ph.D., Ahmad S. Khalil, Ph.D., and Jared Auclair, Ph.D.Business WireThis Dynamic Panel of Experts Will Provide Technical and Strategic Guidance for Kytopen's Research & Development Programs to Support Our Goal of Increasing Patient Access to Lifesaving, Living Medicines Kytopen, an
- 4y agoSGTXSigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsGlobeNewswireIdentified important optimization features for its platform to mitigate PFO risks in current and future programs Advanced iPS cell differentiation protocol for the diabetes program in preparation for anticipated
- 4y agoSGTXSigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsGlobeNewswireCAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported finan
- 4y agoSGTXSigilon Therapeutics Reports First Quarter 2022 Financial Results And Business HighlightsGlobeNewswireOn track to announce results from preclinical studies of SIG-005 in second half of 2022 Current cash position expected to fund operating plans into 2024 CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX),
- 4y agoAXLACDAKDNLIEVLO+7Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING PlatformBusiness WireLatest Financing Round Will Support Tessera's Build Out of its GENE WRITING Platforms and Pursuit of Multiple Therapeutic Programs for Clinical Development Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine
- 4y agoAXLACDAKDNLIEVLO+7Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of AlltrnaPR NewswireWerner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team w
- 4y agoSGTXSigilon Therapeutics to Present at the Needham Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced tha
- 4y agoSGTXSigilon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business HighlightsGlobeNewswireAnnounced strategic reprioritization, with plans to advance mucopolysaccharidosis type I (MPS-1) and diabetes as lead indications as well as continued platform optimization Strengthened leadership team with appointment of new Chief Technical Operation
- 4y agoSGTXSigilon Therapeutics to Present at the Barclays Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced tha
- 4y agoAXLACDAKDNLIEVLO+8Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory AffairsPR NewswireCAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pa
- 4y agoSGTXSigilon Therapeutics Appoints Sarah Yuan, Ph.D., as Chief Technical Operations OfficerGlobeNewswireCAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the
- 4y agoAXLACDAKDNLIEVLO+7INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANTPR NewswireCAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental chall
- 4y agoAXLACDAKDNLIEVLO+8Cellarity Expands Leadership Team to Continue Evolution of a Breakthrough Platform to Encode Biology and Purposefully Create New MedicinesBusiness WireCompany increases industry expertise with the appointments of Laurens Kruidenier, Ph.D., as Chief Scientific Officer; Anna O'Driscoll as Chief People Officer, and Parul Doshi as Senior Vice President, Head of Data and Software Engineering Cellarity,
- 4y agoSGTXSigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium™ on Lysosomal Diseases, MPS-1 and MPS-6GlobeNewswireCAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that
- 4y agoAXLACDAKDNLIEVLO+8Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform BiologyPR NewswireCAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President
- 4y agoAXLACDAKDNLIEVLO+8Flagship Pioneering Announces Appointment of Tom DiLenge as Senior Partner, Global Public Policy, Regulatory & Governmental StrategyPR NewswireCAMBRIDGE, Mass., Jan. 25, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Tom DiLenge has joined the company in a newly created role as Senior Partner, Global Public Policy, Regulatory & Governmental St
- 4y agoSGTXSigilon Therapeutics Announces Strategic ReprioritizationGlobeNewswire- Company plans to prioritize MPS-1 and diabetes with continued focus on platform optimization – - Workforce reduction of approximately 38% – - Anticipated cash runway extended into 2024 – CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE)
- 4y agoAXLACDAKDNLIEVLO+9Cellarity Appoints Biopharmaceutical Executive Ian Estepan to its Board of DirectorsBusiness WireEstepan brings to Cellarity's BOD deep experience and expertise in all aspects of finance, corporate strategy, investor relations, and business development, and a dedication to directly improving patient lives through innovation in medicine Cellarity
- 4y agoSGTXSigilon Therapeutics Announces Update on SIG-001 Phase 1/2 Study in Hemophilia AGlobeNewswireCAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported that
- 4y agoAXLACDAKDNLIEVLO+8Generate Biomedicines Announces First External Equity Raise of $370 Million to Advance Its Drug Generation PlatformBusiness Wire- Generate is harnessing the power of data and machine learning at scale to program biology, dramatically improve the human condition, and democratize biotherapeutics - New capital will enable the company to evolve its technology platform, rapidly sc
- 4y agoAXLACDAKDNLIEVLO+8Flagship Pioneering Announces Appointment of Justine Levin-Allerhand as Senior Partner, Corporate DevelopmentPR NewswireCAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Justine Levin-Allerhand, Ph.D., has joined the company in a newly created role as Senior Partner, Corporate Development. In this
- 5y agoSGTXSigilon Therapeutics Reports Third Quarter 2021 Financial Results and Business HighlightsGlobeNewswireCompany expects to complete its investigation of the clinical hold on its Phase 1/2 trial of SIG-001 in hemophilia A by year-end On track to initiate a Phase 1/2 trial of SIG-005 for MPS-1 in the fourth quarter of 2021 Company appoin
- 5y agoSGTXSigilon Therapeutics to Participate in the Jefferies London Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that
- 5y agoAXLACDAKDNLIEVLO+8Tessera Therapeutics Announces R&D Collaboration with Cystic Fibrosis Foundation as Part of a Portfolio of Complementary Technologies Advanced by Flagship's Pioneering Medicines to Treat Cystic FibrosisBusiness WireTessera's Gene WritingTM Technology is Designed to Simultaneously Correct Multiple Genetic Mutations as well as to Write Genes in Their Entirety Tessera Therapeutics today announced a treatment-focused collaboration with the Cystic Fibrosis Foundatio
- 5y agoAXLACDAKDNLIEVLO+7Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate ChangePR NewswireCAMBRIDGE, Mass., Oct. 13, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into
- 5y agoSGTXSigilon Therapeutics Announces Acceptance of Clinical Trial Application in the UK for SIG-005 for the Treatment of Mucopolysaccharidosis Type IGlobeNewswireCAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced tha
- 5y agoSGTXSigilon Therapeutics to Participate in Two Upcoming Healthcare Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced tha
- 5y agoSGTXSigilon Therapeutics Reports Second Quarter 2021 Financial Results and Business HighlightsGlobeNewswireCAMBRIDGE, Ma., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financi
- 5y agoSGTXSigilon Therapeutics Presents Preclinical Data at the 16th International Symposium on MPS and Related DiseasesGlobeNewswireCAMBRIDGE, Mass., July 23, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported resul
- 5y agoSGTXSigilon Therapeutics Appoints Ajay Rai, M.B.A., as Senior Vice President, Head of Business DevelopmentGlobeNewswireCAMBRIDGE, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the
- 5y agoSGTXSigilon Therapeutics Announces Clinical Hold on SIG-001 Phase 1/2 Study in Hemophilia AGlobeNewswireCAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported that
- 5y agoSGTXSigilon Therapeutics Appoints Brooke Story, M.B.A., to its Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the
- 5y agoAXLACDAKDNLIEVLO+7Tessera Therapeutics Appoints Industry Leaders Elliott Sigal & Mary Rozenman to Board of DirectorsBusiness WireNew Board Members Will Help Advance ‘Gene Writing' Platform and Mission to Cure Disease by Writing in the Code of Life Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of Elliott Sigal, M.D., Ph.D. an
- 5y agoSGTXSigilon Therapeutics Appoints Philip Ashton-Rickardt, Ph.D., as Chief Scientific OfficerGlobeNewswireCAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the
- 5y agoAXLACDAKDNLIEVLO+7Flagship Pioneering Closes $3.4 Billion Capital Pool to Drive Continued Breakthrough Innovations in Human Health and SustainabilityPR NewswireCAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health and sustainability c
- 5y agoSGTXSigilon Therapeutics to Participate in the Jefferies Virtual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that
- 5y agoAXLACDAKDNLIEVLO+7Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological AgriculturePR NewswireCAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges,
- 5y agoAXLACDAKDNLIEVLO+7Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus GreeningPR NewswireCAMBRIDGE, Mass., May 19, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, a
- 5y agoSGTXSigilon Therapeutics Reports First Quarter 2021 Financial Results and Business HighlightsGlobeNewswireCAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financ
- 5y agoSGTXFlagship Pioneering Unveils Laronde to Advance Endless RNA™ - A New Class of Programmable Medicines Capable of Expressing Therapeutic Proteins Inside the BodyPR NewswireCAMBRIDGE, Mass., May 10, 2021 /PRNewswire/ -- Flagship Pioneering today unveiled Laronde, a platform company developing Endless RNA™ (eRNA), a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body. Flag
- 5y agoSGTXSigilon Therapeutics to Present at the BofA Securities 2021 Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that